Evaluation of mesalazine polymeric conjugate in the treatment of actinic proctitis in rats

Acta Cir Bras. 2021 Oct 8;36(8):e360805. doi: 10.1590/ACB360805. eCollection 2021.

Abstract

Purpose: The present study aimed at testing a new formulation of mesalazine linked to chondroitin sulfate and its components alone in the treatment of actinic proctitis in rats.

Methods: Forty-seven female Wistar rats were submitted to pelvic radiation and divided into eight groups: control A, mesalazine A, chondroitin A, and conjugate A, gavage of the according substance two weeks after irradiation and sacrifice three weeks after oral treatment; control C, mesalazine C, chondroitin C, and conjugate C, sacrifice six weeks after oral treatment. The rectum was submitted to histological characterization for each of the findings: inflammatory infiltrate, epithelial degeneration, mucosal necrosis, and fibrosis.

Results: The inflammatory infiltrate was more intense in chondroitin A, mesalazine A, and conjugate C. The collagen deposition was less intense in chondroitin A, and mesalazine A, and more intense in control C.

Conclusions: Mesalazine and chondroitin alone were efficacious in inducing a delayed inflammatory response, hence reducing the late fibrosis. The conjugate was able to induce an ever more delayed inflammatory response.

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Female
  • Mesalamine / therapeutic use
  • Proctitis* / drug therapy
  • Rats
  • Rats, Wistar
  • Rectum

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Mesalamine